Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503239 | 0.83 | MGAM (0.30) | MGAMGAASIMGAM2 | |
| SCHEMBL3228082 | 0.78 | THRB (0.32) | LMNA | |
| SCHEMBL497771 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL5047600 | 0.78 | LMNA (0.33) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL12272261 | 0.78 | SOAT1 (0.32) | LMNASOAT1 | |
| SCHEMBL10386529 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10561417 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL30031260 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL18446 | 0.77 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL21582004 | 0.75 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | ALDH1A1 209/4885LMNA 4267/4885HSD17B10 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.